Vice President, Disease Area Leader-Neuromuscular Disease
Core
Strategic and operational leader for late-stage clinical development of neuro-immunology programs, specifically telitacicept for neuromuscular diseases.
Role type
Vice President, Disease Area Leader (Neuromuscular)
Builds
Late-stage clinical programs for telitacicept (dual BAFF/APRIL inhibitor) targeting myasthenia gravis, lupus, IgA nephropathy, and Sjögren's syndrome.
Domain
Biotechnology / Neuro-immunology / Autoimmune Disease
Deliverable
production ML models | product features | dashboards & analysis | research | client delivery | infrastructure | physical/clinical work
Required skills
Late-stage clinical program leadership, regulatory agency interaction, study design and execution, statistical analysis planning, cross-functional team management, external scientific engagement, strategic portfolio prioritization
Preferred skills
Small-biotech experience, deep neuromuscular disease expertise, Phase 2b/3 trial leadership
Technologies
telitacicept, BAFF/APRIL inhibitors
Responsibilities
Define and lead late-stage development strategy; drive portfolio prioritization and scenario planning; lead design and execution of registration-enabling studies; provide senior medical oversight of clinical trials; contribute to global regulatory strategy and lead interactions with FDA/EMA; mentor and develop high-performing clinical teams; build relationships with key opinion leaders and patient advocacy groups.
Seniority
Executive (VP), strategic & hands-on leadership
